PR is a 45 y/o male that has been recently diagnosed with early stages of Parkinson's Disease. You put PR on a dopaminergic agent (dopamine agonist), which of the following agents is an appropriate first line treatment? Select one:

Scabies is a contagious skin infestation caused by the mite Sarcoptes scabiei, which burrows into the epidermis and causes intense itching and a papular rash. Transmission commonly occurs through prolonged skin-to-skin contact, making household spread very common. Effective management requires both pharmacologic treatment and prevention of reinfestation. Treating close contacts and addressing environmental contamination are essential parts of care.

Rationale:
A. All family members and close household contacts should be treated simultaneously, even if they do not yet have symptoms. Symptoms may take several weeks to appear after initial infestation, but transmission can still occur during this asymptomatic period. Simultaneous treatment prevents reinfestation cycles and is a standard recommendation in scabies management to ensure complete eradication.

B. Treatment is not best with oral therapies because first-line management is usually with topical scabicides such as Permethrin 5% cream. Oral Ivermectin may be used in certain severe cases such as crusted scabies or outbreaks, but it is not the routine initial therapy for uncomplicated infestations. Topical treatment remains the preferred standard in most patients.

C. Itching does not resolve immediately after treatment and may persist for several weeks despite successful eradication of the mites. This continued itching occurs because of an ongoing hypersensitivity reaction to dead mites and their products. Patients should be taught that persistent itching does not necessarily mean treatment failure, which helps reduce unnecessary retreatment.

D. Lindane is not the medication of choice during pregnancy because of its potential neurotoxicity and risk of systemic absorption. It is generally avoided in pregnant patients, infants, and individuals with seizure disorders. Safer alternatives such as permethrin are preferred because they have a better safety profile and are more effective.

Clozapine (Clozaril) is an atypical antipsychotic used for treatment-resistant schizophrenia when other antipsychotics have failed. It is highly effective in reducing psychotic symptoms, especially in refractory cases, but its use is limited by serious and potentially life-threatening adverse effects. Because of these risks, it requires strict hematologic monitoring and is only used under specialized prescribing programs. Its safety profile is the main reason it is not first-line therapy.

Rationale:
A. Clozapine is not reserved for refractory schizophrenia due to cost, even though it may be more expensive than other antipsychotics. The primary limitation to its use is safety, not financial factors. Clinical decision-making is based on risk of serious adverse effects rather than medication cost alone.

B. Clozapine does not primarily mask hypoglycemia symptoms. While some antipsychotics can affect metabolic regulation and increase the risk of diabetes, masking hypoglycemia is not a key reason for restricted use of Clozapine (Clozaril). The major concern is hematologic toxicity rather than glucose symptom masking.

C. QTc prolongation can occur with some antipsychotics, but it is not the most significant or defining risk that restricts use of Clozapine (Clozaril). While cardiac monitoring is important, other agents such as ziprasidone have more prominent QTc concerns. Clozapine’s restriction is primarily driven by hematologic toxicity.

D. Clozapine carries a risk of severe and potentially fatal agranulocytosis, which is a profound decrease in white blood cells that can lead to life-threatening infections. Because of this risk, patients require mandatory regular absolute neutrophil count (ANC) monitoring under strict protocols. This serious hematologic adverse effect is the main reason Clozapine (Clozaril) is reserved for treatment-resistant schizophrenia.